Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Expression of BTLA/HVEM axis in hematological and prospects for immune target therapy].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
Department of Hematology, Lanzhou University Second Hospital, Lanzhou 730000, China. *Corresponding authors, E-mail:
Article Synopsis
- BTLA is an inhibitory immune checkpoint that interacts with HVEM to regulate immune balance and maintain immune tolerance on the same cell, while also affecting different immune cells to suppress immune responses.
- Dysregulation of the BTLA/HVEM interaction can lead to impaired immune cell function, allowing tumor cells to evade immune detection and progress.
- Research indicates that BTLA and HVEM are often abnormally expressed in various tumors, making them potential targets for future immunotherapy approaches in treating hematologic malignancies.
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications.
Exp Hematol Oncol
January 2025
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430300, China.
Article Synopsis
- Immune checkpoint therapies have revolutionized cancer treatment but face challenges like low response rates and drug resistance, highlighting the need for a better understanding of the tumor microenvironment (TME).
- Recent studies show that biomechanical forces within the TME significantly impact immune responses and tumor progression, indicating that manipulating these forces could enhance immune activation against tumors.
- The review discusses key biomechanical mechanisms, the role of the extracellular matrix, and potential clinical applications, aiming to provide insights for discovering new therapeutic targets.
Integrated RNA sequencing analysis and machine learning identifies a metabolism-related prognostic signature in clear cell renal cell carcinoma.
Sci Rep
January 2025
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
The connection between metabolic reprogramming and tumor progression has been demonstrated in an increasing number of researches. However, further research is required to identify how metabolic reprogramming affects interpatient heterogeneity and prognosis in clear cell renal cell carcinoma (ccRCC). In this work, single-cell RNA sequencing (scRNA-seq) based deconvolution was utilized to create a malignant cell hierarchy with metabolic differences and to investigate the relationship between metabolic biomarkers and prognosis.
View Article and Find Full Text PDFComprehensive analysis of targetable mutations and tumor microenvironment in urachal cancer.
NPJ Precis Oncol
January 2025
University of California, Irvine, Orange, CA, 92868, USA.
Urachal cancer, a rare malignancy, generally presents in the clinical setting with advanced stages of disease. Systemic treatment with chemotherapy is generally utilized in this setting. However, there remains a paucity of data on the effectiveness of immune checkpoint inhibitors or targeted therapies for urachal cancer.
View Article and Find Full Text PDFTACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma.
Lancet
January 2025
Division of Hepatology, Department of Medicine II, University Hospital Würzburg, Würzburg 97080, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!